Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Assessing Safety and Efficacy of Sintilimab and Metformin Combination Therapy in SCLC

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03994744
Recruitment Status : Recruiting
First Posted : June 21, 2019
Last Update Posted : August 28, 2019
Xiangya Hospital of Central South University
Innovent Biologics (Suzhou) Co. Ltd.
Information provided by (Responsible Party):
Lin Wu, Hunan Cancer Hospital

Brief Summary:

In this Single arm study, histologically or cytologically confirmed ED-stage small cell lung cancer (SCLC) patients resistant to or relapsed after standard chemotherapy will be enrolled to investigate the Efficacy and Safety of a Combination of Sintilimab and Metformin.

Primary outcome:

Objective response rate (ORR), Safety of the combination therapy

Secondary outcome:

Overall survival (OS), Progression-free survival (PFS), Duration of response(DOR),

Condition or disease Intervention/treatment Phase
Small-cell Lung Cancer Small Cell Lung Carcinoma Small Cell Lung Cancer Recurrent Small Cell Lung Cancer Extensive Stage Drug: PD-1 inhibitor Drug: Metformin Phase 2

Detailed Description:

Exploratory Endpoints:

The association between the efficacy of the combination treatment and changes in CTC counts after administration of the treatment.

Evaluating the correlation between programmed death ligand 1 (PD-L1) expression derived from circulating tumor cells (CTC) and tumor tissue cells, and the predictive role of CTC PD-L1 expression in ED-SCLC.

The compositional changes in the gut microbiota after administration of the treatment and its association with the efficacy of the combination treatment.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 68 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description:

Patients fulfilling Eligibility Criteria will be included in our study. Participants will be given intravenous administration of Sintilimab (1200mg/3w).

Metformin treatment will be given (day20) 1 week before the second administration of Sintilimab at a dose of 2000 mg daily (1000mg BID).

Treatments will be administrated for one year or until disease progression, death, or unacceptable toxicity.

Regular follow-up and safety assessment: Patients were assessed for drug safety and treatment efficacy every 2 cycles (6 weeks) in the first 3 months after enrollment, and then evaluated every 4 cycles (12 weeks). Assessment of tumor response, adverse events. Follow-up until disease progression and patient death.

Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Open-label, Single-arm Study Assessing the Efficacy and Safety of Combination Therapy of Sintilimab and Metformin With Relapsed PD-L1 Positive Small Cell Lung Cancer
Actual Study Start Date : August 20, 2019
Estimated Primary Completion Date : August 1, 2021
Estimated Study Completion Date : July 1, 2022

Arm Intervention/treatment
Experimental: Sintilimab and Metformin

Participants will be given intravenous administration of Sintilimab (1200mg/3w) Metformin treatment will be given (day20) 1 week before the second administration of Sintilimab a a dose of 2000 mg daily (1000mg BID).

The duration of treatment will be up to one year, or till the disease progression, death, or unacceptable toxicity show up.

Drug: PD-1 inhibitor
Intravenous administration of Sintilimab (1200mg/3weeks)
Other Names:
  • Sintilimab
  • IBI380

Drug: Metformin

Metformin treatment will be given (day20) 1 week before the second administration of Sintilimab at a dose of 2000 mg daily (1000mg BID).

To reduce GI toxicity, participants start Metformin at 1000 mg daily (500mg am, 500 mg pm) for 1 week.

Primary Outcome Measures :
  1. Objective response rate of Sintilimab and Metformin(ORR) [ Time Frame: 1 year ]
    Assessing the response of treatment of each patient using RECIST 1.1 criteria, the investigators calculate the percentage of patients meet partial response (30% decrease in diameter) and complete response in the arm.

  2. Safety of the combination therapy of Sintilimab and Metformin: CTCAE4.03 grading [ Time Frame: 2 year ]
    Incidence and severity of (serious) adverse events in each individual according to the CTCAE4.03 grading.

Secondary Outcome Measures :
  1. Median overall survival (OS) time of Sintilimab and Metformin [ Time Frame: 2 years ]
    Use K-M to estimate the median OS of single arm.

  2. Median progression free survival(PFS) of Sintilimab and Metformin [ Time Frame: 1 year ]
    Use K-M to estimate the median PFS of single arm.

  3. Median duration of response (DoR) of Sintilimab and Metformin [ Time Frame: 1 year ]
    Use K-M to estimate the median DoR of single arm.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male or female patient, age≥18 and≤65;
  2. Eastern Cooperative Oncology Group (ECOG) performance status ≤2;
  3. The life expectancy of greater than 12 weeks;
  4. Participants must have histologically or cytologically confirmed metastatic or extended disease of SCLC (ED-SCLC).
  5. According to RECIST1.1, participants must have been confirmed Disease progression (within 6 months, confirmed by imaging test)after platinum-based doublet chemotherapy OR after (PFS>6 months, ) platinum-based doublet chemotherapy and refused to continue chemotherapy, OR after second-line or more lines of systemic chemotherapy limited disease SCLC (LD-SCLC) patients with disease progression after Synchronous chemoradiotherapy, must receive firstline systematic platinum-based doublet chemotherapy and refused to receive chemotherapy again.
  6. Evaluable or measurable lesion is required, defined as at least one lesion (not brain metastasis) that can be accurately measured based on RECIST 1.1;
  7. Participant need to provided tumor tissue (from an archival tumor sample obtained within 1 year or from a new biopsy sample) for PD-L1 immunohistochemical (IHC) assay, and PD-L1expression in more than 1% cells is required;
  8. Participant is able to the ability to swallow oral medications
  9. Participants have to meet the following criteria to ensure function of vital organs:

    Absolute neutrophil count (ANC) ≥1.5×109/L or White blood cell count >3.5×109/L;Platelets >80×109/L; Hemoglobin (HGB)≥90 g/L;Serum total bilirubin ≤ 1.5 x upper limit of normal (ULN); AST(SGOT)/ALT(SGPT) ≤2.5 ×ULN; ALB≥2.8g/dL;Serum creatinine ≤ 1.5 x institutional ULN OR creatinine clearance ≥40 mL/min using the Cockcroft-Gault equation

  10. Participants must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) through the treatment, and for at least 180 days after the last dose of study treatment; Participants must have the ability to understand and be willing to sign a written informed consent document.

Exclusion Criteria:

  1. Participants who were diagnosed as mixed pathological type of small cell lung cancer
  2. Participants who had long-term use of metformin (>2 weeks) 6 months prior to study entry, or diagnosed with type-2 diabetes,
  3. Participants received treatment with anti-PD1, -PDL1, -CTLA4, -CD137 inhibitors before, or any therapy specifically targeting T-cell co-stimulation or checkpoint pathways.
  4. Participants received cellular immunotherapy before
  5. Participants with Uncontrolled intercurrent illness including, but not limited to:

    Ongoing or active infection; Known history of Human Immunodeficiency Virus (HIV) infection Acute or chronic active hepatitis B (HBV DNA >1*10^3 copies/ml or >200 IU/mL) or, acute or chronic active hepatitis C (with a positive Hepatitis C antibody test result) Active tuberculosis Congestive heart failure (Class III-IV, according to New York Heart Association classification), or and clinically significant Cardiac arrhythmia if poorly controlled; Uncontrolled arterial hypertension (systolic blood pressure ≥160mmHg or diastolic blood pressure ≥100mmHg) Any arterial thrombosis, embolism, ischemia, myocardial infarction, unstable angina, or cerebrovascular accident within 6 months prior to enrollment,

  6. Participants with symptomatic Central nervous metastasis or meningeal carcinomatosis are excluded; Participants with asymptomatic brain metastases or with brain metastases that have been treated and stable in a subsequent scan are allowed to include if there is measurable lesion outside the Central nervous system and no history of intracranial hemorrhage, and not midbrain, pons, cerebellum, medulla or spinal cord metastasis, and do not need glucocorticoid therapy.
  7. Participants receiving glucocorticoid (>30 mg prednisone equivalent a day) or any Immunosuppressive drug within 14 days prior to study recruitment; Participants receiving inhaled or Topical corticosteroids, adrenal corticosteroid replacement therapy (>10 mg prednisone equivalent a day) are allowed if they have no active autoimmune disease
  8. Participants with a known additional malignancy (Except for Non-melanoma skin cancer and the following in situ carcinoma: in situ bladder carcinoma, in situ gastric carcinoma, in situ colonic carcinoma, in situ endometrial carcinoma, in situ cervical carcinoma /dysplasia, in situ melanoma carcinoma and in situ breast Carcinoma) unless they Maintained Complete Remission for at least 5 years and do not need corresponding treatment during the study
  9. Participants who have not recovered (i.e., ≤ Grade 1 according to NCI CTCAE V4or at baseline) from adverse effects due to a previously administered agent.
  10. Participants who have uncontrollable effusion, such as pleural and ascites that cannot be controlled by drainage or other treatment
  11. Patients who have active autoimmune diseases; excluding patients whose active autoimmune disease is caused by Vitiligo or asthma that is completely relieved in childhood and Patients with hypothyroidism requiring only hormone replacement therapy
  12. Patients with known Allogeneic organ transplantation (except corneal transplantation) or allogeneic hematopoietic stem cell transplantation
  13. Patients who are pregnant or breastfeeding,
  14. Patients who are allergic to monoclonal antibody drugs
  15. Patients who have contraindications to metformin including severe allergic reactions and intolerance
  16. Patients who are not eligible for this study, as Assessed by Investigator

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03994744

Layout table for location contacts
Contact: Lin Wu, Prof. +86 13170419973
Contact: Xingxiang Pu, Prof. +86 15874180022

Layout table for location information
China, Hunan
Hunan Cancer hospital Recruiting
Changsha, Hunan, China, 410000
Contact: Xing xiang Pu, Dr.    +86 0731-89762301   
Contact: Lin Wu, Dr.    +86 0731-89762300   
Principal Investigator: Lin Wu         
Sub-Investigator: Xingxiang Pu         
Sponsors and Collaborators
Hunan Cancer Hospital
Xiangya Hospital of Central South University
Innovent Biologics (Suzhou) Co. Ltd.
Layout table for investigator information
Principal Investigator: Lin Wu Hunan Cancer Hospital
Layout table for additonal information
Responsible Party: Lin Wu, Chief physician, director of department, Hunan Cancer Hospital Identifier: NCT03994744    
Other Study ID Numbers: HNCH-SCLC-2019260
First Posted: June 21, 2019    Key Record Dates
Last Update Posted: August 28, 2019
Last Verified: August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on only as required by federal regulation or as a condition of awards and agreements supporting the research
Supporting Materials: Study Protocol
Time Frame: Data can be shared no earlier than 1 year following the date of publication
Access Criteria: please contact the principal investigator of this study or correspondence author of published wotk.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Lin Wu, Hunan Cancer Hospital:
PD-1 checkpoint inhibitor
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Small Cell Lung Carcinoma
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Immune Checkpoint Inhibitors
Hypoglycemic Agents
Physiological Effects of Drugs
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents